News/ Sales and Marketing/ US Neurocrine achieves a first with tardive dyskinesia drug Ingrezza Andrew McConaghie FDA approvals 2017, Ingrezza, Neurocrine Bioscience 0 Comment The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The Share X Neurocrine achieves a first with tardive dyskinesia drug Ingrezza https://pharmaphorum.com/news/ingrezza-approved/
FDA approvals 2017, Ingrezza, Neurocrine Bioscience
0 Comment
